CytoDyn Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)		1 Months Ended		2 Months Ended
Subsequent Events (Details) - USD ($)	Apr. 03, 2024	Mar. 31, 2024	Dec. 31, 2023	Apr. 30, 2024	Feb. 29, 2024	Nov. 30, 2023	Sep. 30, 2023	Jul. 31, 2023	Jun. 30, 2023	Jun. 30, 2022
Subsequent Event [Line Items]
Warrants to purchase common shares, shares							21,500,000
Term of warrants							5 years
Exercise price of share							$ 0.50	$ 0.306	$ 0.306	$ 0.50
Warrant covering common stock shares purchased, percentage			13.00%
Side Letter Agreement With Samsung
Subsequent Event [Line Items]
Contractual obligation	$ 43,800,000
Placement agent notes
Subsequent Event [Line Items]
Convertible note, aggregate principal									$ 2,300,000
Term of warrants			10 years			10 years
Partitioned Notes
Subsequent Event [Line Items]
Convertible note, aggregate principal					$ 4,800,000
Third Private Placement [Member]
Subsequent Event [Line Items]
Warrants to purchase common shares, shares			18,200,000
Term of warrants			5 years
Exercise price of share			$ 0.21
Third Private Placement [Member] \| Placement agent notes
Subsequent Event [Line Items]
Number of common shares in a fixed combination issue of shares			1
Number of warrants in a fixed combination issue of securities			1
Number of shares			1
Closing share price (as percentage)			90.00%
Subsequent Event \| Side Letter Agreement With Samsung
Subsequent Event [Line Items]
Contractual obligation	43,800,000
Contractual obligation, non contingent amount	$ 250,000
Contractual obligation, percentage of qualifying revenue agreed to pay	20.00%
Subsequent Event \| Partitioned Notes
Subsequent Event [Line Items]
Convertible note, aggregate principal		$ 500,000
Subsequent Event \| Long-term Convertible Note - April 23, 2021 Note
Subsequent Event [Line Items]
Conversion of preferred stock to common stock (in shares)		3,400,000
Subsequent Event \| Third Private Placement [Member] \| Placement agent notes
Subsequent Event [Line Items]
Proceeds, net of issuance costs		$ 2,800,000
Consideration received from sale of stock		$ 2,500,000		$ 2,500,000
Warrants to purchase common shares, shares		16,900,000
Term of warrants		5 years
Exercise price of share		$ 0.21
Number of common shares in a fixed combination issue of shares		1
Number of warrants in a fixed combination issue of securities		1
Number of shares		1
Exercise price of stock warrant combo, per share		$ 0.17
Closing share price (as percentage)		90.00%
Stock issued for private offerings (in shares)		16,900,000